1. Home /
  2. Pharmaceuticals

Pharmaceuticals

Amgen Charts Indicate Shares Want to Work Their Way Higher Longer Term

Amgen Charts Indicate Shares Want to Work Their Way Higher Longer Term

Amgen's deal to buy Otezla from Celgene should not deter the drugmaker's stock from gaining ground over the long haul.

Put the Pajamas Away: Jim Cramer on U.S.-China Trade and Amgen

Put the Pajamas Away: Jim Cramer on U.S.-China Trade and Amgen

Jim Cramer weighs in on the U.S.-China trade war and Amgen.

Amgen Adds Celgene's Otezla to Bolster Pipeline at Pricey Valuation

Amgen Adds Celgene's Otezla to Bolster Pipeline at Pricey Valuation

Amgen is finally making an expected splash out of its cash pile, but questions are abounding about the cost paid for Celgene's Otezla.

Amgen to Acquire Celgene's Otezla for $13.4 Billion in Cash

Amgen to Acquire Celgene's Otezla for $13.4 Billion in Cash

Amgen will acquire the global rights to Celgene's oral psoriasis treatment Otezla for $13.4 billion in cash, paving the way for Bristol Myers-Squibb to compete its acquisition of Celgene.

A Pair of Rare Disease Biotech Concerns Worth a Good Look

A Pair of Rare Disease Biotech Concerns Worth a Good Look

Alexion Pharmaceuticals is a solid company that is the subject of acquisition rumors and Amicus Therapeutics has a key drug off to a strong start.

Alexion Higher on Spanish Report, Cited by Analyst, That Amgen Will Make Bid

Alexion Higher on Spanish Report, Cited by Analyst, That Amgen Will Make Bid

Mizuho's Salim Syed says talk of possible tieup isn't far-fetched. Alexion and Amgen decline comment.

Endo Surges as Opioid Maker Reaches Settlement in Landmark Lawsuit

Endo Surges as Opioid Maker Reaches Settlement in Landmark Lawsuit

Endo's stock price surges after the company announces a settlement with Cuyahoga and Summit counties, removing the company from a potentially damaging trial in state court in October.

How to Extract Pretty Profits from Ugly Stocks

How to Extract Pretty Profits from Ugly Stocks

It's a process that involves harvesting gains by repeatedly writing call options against stocks steadily in decline.

Amarin Shares Show Heart as Anti-Cholesterol Drug Firm Bucks Market Rout

Amarin Shares Show Heart as Anti-Cholesterol Drug Firm Bucks Market Rout

Amarin's stock jumped after SVB Leerink upped its rating on the biotech's stock to outperform, saying a recent double-digit decline offers a buying opportunity.

Deciphera Soars on Positive Phase III Drug Trial

Deciphera Soars on Positive Phase III Drug Trial

Deciphera Pharma stock more than doubled on positive results from a Phase III clinical study of its drug to treat patients with advanced gastrointestinal stromal tumors.